I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse
Metaiodobenzylguanidine (MIBG) has been used for the detection and treatment of neuroectodermal tumors, including neuroblastoma. We report our experience with /sup 131/I-MIBG used diagnostically in neuroblastoma patients with relapse. Thirty-eight studies were performed in 26 patients. There were 24 children (range 3 months-14 years) and two adults. While the study was found to be both sensitive and specific for the presence of disease, there are instances of discordance. False-negative studies were found with a markedly anaplastic tumor and with two mature ganglioneuromas. A bone lesion was negative with /sup 131/I-MIBG, but positive on bone scan. A biopsy confirmed the presence of neuroblastoma. Caution should be exercised when scanning pretreated patients, and perhaps with newly diagnosed patients as well.
- Research Organization:
- Children's Hospital, Philadelphia, PA (USA)
- OSTI ID:
- 6601442
- Journal Information:
- Med. Pediatr. Oncol.; (United States), Vol. 16:5
- Country of Publication:
- United States
- Language:
- English
Similar Records
Treatment of neuroblastoma with /sup 131/I-metaiodobenzylguanidine
Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial
Related Subjects
NEOPLASMS
DIAGNOSIS
NERVES
RADIOPHARMACEUTICALS
DIAGNOSTIC USES
IODINE 131
PATIENTS
RADIOISOTOPE SCANNING
SPECIFICITY
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
NERVOUS SYSTEM
NUCLEI
ODD-EVEN NUCLEI
RADIOISOTOPES
USES
550601* - Medicine- Unsealed Radionuclides in Diagnostics